Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine
Open Access
- 3 February 2021
- Vol. 9 (2), 118
- https://doi.org/10.3390/vaccines9020118
Abstract
Tobacco smoking continues to be a global epidemic and the leading preventable cause of cancer and cardiovascular disease. Nicotine vaccines have been investigated as an alternative to currently available smoking cessation strategies as a means to increase rates of success and long-term abstinence. Recently, we demonstrated that a mucosal nicotine vaccine was able to induce robust mucosal and systemic antibodies when delivered heterologously using intranasal and intramuscular routes. Herein, we investigated the neutralization ability of the anti-nicotine antibodies using both intranasal and intracardiac nicotine challenges. Combining the extraction of lyophilized organ samples with RP-HPLC methods, we were able to recover between 47% and 56% of the nicotine administered from the blood, brain, heart, and lungs up to 10 min after challenge, suggesting that the interaction of the antibodies with nicotine forms a stable complex independently of the route of vaccination or challenge. Although both challenge routes can be used for assessing systemic antibodies, only the intranasal administration of nicotine, which is more physiologically similar to the inhalation of nicotine, permitted the crucial interaction of nicotine with the mucosal antibodies generated using the heterologous vaccination route. Notably, these results were obtained 6 months after the final vaccination, demonstrating stable mucosal and systemic antibody responses.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT-148531)
- Northern Cancer Foundation (NCF 2017-2019)
This publication has 34 references indexed in Scilit:
- Development of vaccines to treat opioid use disorders and reduce incidence of overdoseNeuropharmacology, 2019
- Current advances in research in treatment and recovery: Nicotine addictionScience Advances, 2019
- Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routesPLOS ONE, 2019
- Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)Heliyon, 2016
- Is immunotherapy an opportunity for effective treatment of drug addiction?Vaccine, 2015
- New Directions in Nicotine Vaccine Design and UsePublished by Elsevier BV ,2014
- Therapeutic vaccines against tobacco addictionExpert Review of Vaccines, 2013
- Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine ImmunotherapeuticClinical Pharmacology & Therapeutics, 2011
- Safety and immunogenicity of a nicotine conjugate vaccine in current smokersClinical Pharmacology & Therapeutics, 2005
- A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicityEuropean Journal of Immunology, 2005